BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28298076)

  • 1. Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study.
    Baek SW; Moon JY; Ryu H; Choi YS; Song IC; Lee HJ; Yun HJ; Kim S; Jo DY
    Korean J Intern Med; 2018 Jul; 33(4):790-797. PubMed ID: 28298076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].
    Kim JT; Cho YG; Choi SI; Lee YJ; Kim HR; Jang SJ; Moon DS; Park YJ; Park G
    Korean J Lab Med; 2010 Dec; 30(6):567-74. PubMed ID: 21157140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms.
    Christensen AS; Møller JB; Hasselbalch HC
    Leuk Res; 2014 Apr; 38(4):490-5. PubMed ID: 24630365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
    Lin Y; Liu E; Sun Q; Ma J; Li Q; Cao Z; Wang J; Jia Y; Zhang H; Song Z; Ai X; Shi L; Feng X; Li C; Wang J; Ru K
    Am J Clin Pathol; 2015 Jul; 144(1):165-71. PubMed ID: 26071474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-Reducing Genetic Variant of Wilms Tumor 1 Gene rs16754 in Korean Patients With BCR-ABL1-Negative Myeloproliferative Neoplasm.
    Kim N; Kim IS; Chang CL; Kang JE; Lee EY; Shin HJ
    Ann Lab Med; 2015 May; 35(3):348-51. PubMed ID: 25932444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
    Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E
    Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
    Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
    Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
    Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
    Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms.
    Kim J; Byun JM; Hong J; Koh Y; Shin DY; Kim I; Yoon SS; Park H; Bang SM
    Sci Rep; 2021 Sep; 11(1):17819. PubMed ID: 34497309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
    Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
    Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
    Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.
    Singh S; Kaur K; Paul D; Jain K; Singh J; Narang V; Garg B; Sood N; Dhillon B
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e569-e578. PubMed ID: 33757770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN.
    Stegelmann F; Wille K; Busen H; Fuchs C; Schauer S; Sadjadian P; Becker T; Kolatzki V; Döhner H; Stadler R; ; Döhner K; Griesshammer M
    Leukemia; 2021 Feb; 35(2):628-631. PubMed ID: 32616864
    [No Abstract]   [Full Text] [Related]  

  • 17. [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
    Lyu XD; Li YW; Guo Z; Xin YP; Hu JY; Fan RH; Song YP
    Zhonghua Nei Ke Za Zhi; 2020 Jan; 59(1):35-39. PubMed ID: 31887834
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.
    Shaikh AB; Aribandi A; Gupta A; Subramanian SK; Goyal M
    Indian J Pathol Microbiol; 2021; 64(4):820-823. PubMed ID: 34673614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.
    Schnittger S; Bacher U; Eder C; Dicker F; Alpermann T; Grossmann V; Kohlmann A; Kern W; Haferlach C; Haferlach T
    Haematologica; 2012 Oct; 97(10):1582-5. PubMed ID: 22511494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.
    Aswad MH; Kissová J; Rihova L; Zavrelova J; Ovesná P; Penka M
    Klin Onkol; 2019; 32(2):109-116. PubMed ID: 30995850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.